Under the agreement, which is supported by OHSU Proteomics Shared Resource, the institute will tap Ymir’s proprietary urinary extracellular vesicle technology. Ymir’s technology isolates extracellular vesicles and analyzes miRNA profiles of urine samples from liver cancer patients and high-risk cirrhotic patients. OHSU will then study the same vesicles and determine protein profiles.
“It’s exciting to be collaborating with the team at Ymir on this project. This is a wonderful example of what can be accomplished when bringing basic scientists, clinicians and industry together,” said Larry David, PhD, director of the OHSU Proteomics Shared Resource. “The work dovetails quite well with the major research goal of the Knight Cancer Institute, which is to be able to detect cancers earlier so they can be more effectively treated.”
More articles on data analytics & precision medicine:
Geisinger launches national precision medicine initiative, appoints Huntington Willard director
AMA CEO outlines opportunities for health data
NantHealth’s genetic cancer tests revenue exceeds $1M in Q3: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
